IRVING, Texas--(BUSINESS WIRE)--Almirall, S.A., the global pharmaceutical company based in Barcelona, will continue to rely on legal channels to defend itself against Viveve’s patent infringement suit, after having been notified of the denial by the District Court for the Eastern District of Texas of ThermiGen, LLC's motions to dismiss the Viveve suit. The decision specifically confirms that the lawsuit has no effect on physicians offering the ThermiVa procedure in their practices.
Paul Herchman stated “As we expected, this lawsuit has no effect on the over 1,000 physician’s offering the ThermiVa procedure in their practices, as expressly found by the presiding United States District Court judge, The Honorable Rodney Gilstrap, in his Opinion and Order of April 20, 2017.”
Almirall and Thermi will continue to vigorously seek by legal means a decision that Thermi does not infringe Viveve’s patent and that such patent should be invalidated.
ThermiVa is FDA cleared for use in dermatological and general surgical procedures for electrocoagulation and hemostasis; and to create lesions in nerve tissue. The ThermiVa probe, which is designed for transcutaneous RF application to vulvovaginal tissue, is the subject of a specific patent application.
For more information please contact Wendy Oseas, V.P. Global Marketing or visit: http://www.thermi.com/
Almirall is a global pharmaceutical company with a strong focus in Dermatology and Aesthetics with the mission of providing valuable medicines and medical devices to you and future generations. Our R&D is focused on Dermatology, with a wide range of programs including key indications. Through our innovative products, agreements and alliances, our work covers the entire drug value chain. Almirall is continually growing as a specialist company in a wide range of skin diseases, in order to cover our customers unmet needs.
Founded in 1943, headquartered in Barcelona, Spain, Almirall is listed on the Spanish Stock Exchange (ticker: ALM) and it has become a source of value creation for society due to its vision and the commitment of its long-standing major shareholders. In 2016, its revenues totaled 859.3 million euros and, with more than 2.000 employees, it has gradually built up a trusted presence across Europe, as well as in the US.
For more information, please visit www.almirall.com.
The Thermi flagship product is the ThermiRF®, Temperature Controlled Radio Frequency Generator System, which is FDA cleared for dermatological and general surgical procedures for electrocoagulation and hemostasis, and to create lesions in nervous tissue. ThermiRF, is an advanced technology using finely controlled thermal energy. It is a multi-use platform which uses proprietary hand pieces designed for specific medical applications and promotes increased patient safety and clinical effectiveness, while providing versatile solutions for physicians serving the aesthetic market.
The Thermi250® also employs temperature-controlled radio frequency using a specially designed thermistor’s regulated hand piece, which delivers precise heating to the skin’s surface.
For more information, please visit www.thermi.com.
This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are "forward-looking statements". These statements are based on currently available information and on best estimates and assumptions believed to be reasonable by the Company. These statements involve risks and uncertainties beyond the Company's control. Therefore, actual results may differ materially from those stated by such forward-looking statements. The Company expressly disclaims any obligation to review or update any forward-looking statements, targets or estimates contained in this document to reflect any change in the assumptions, events or circumstances on which such forward-looking statements are based unless so required by applicable law.